Disease Overview
Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with psoriasis, which is classified within the group of spondyloarthritis. With the exception of the distal interphalangeal joints (hands and feet), there are no predictable joints for involvement in PsA, and the signs of inflammation are often more difficult to detect than those associated with rheumatoid arthritis. PsA is common in patients with psoriasis, and there is some evidence to suggest that the severity of psoriasis is associated with an increased risk for – although not greater severity of – PsA.
Market Snapshot
Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with psoriasis, which is classified within the group of spondyloarthritis. With the exception of the distal interphalangeal joints (hands and feet), there are no predictable joints for involvement in PsA, and the signs of inflammation are often more difficult to detect than those associated with rheumatoid arthritis. PsA is common in patients with psoriasis, and there is some evidence to suggest that the severity of psoriasis is associated with an increased risk for – although not greater severity of – PsA.
Market Snapshot
- Cosentyx will displace Stelara as the preferred biologic in the post-TNF setting.
- Humira is the preferred biologic to treat PsA due to its efficacy in skin and joint symptoms.
- A modest 6.8% increase in the diagnosed prevalent population of psoriatic arthritis is forecasted during 2017–37.
- The increasing availability of novel biologic therapies is set to intensify competition in the post-TNF setting.
- Product differentiation is critical for new biologic and small molecule therapies attempting to enter the market.
- Biosimilar TNF-alpha inhibitors present the greatest challenge to wider uptake of Cosentyx and Taltz.
Table of Contents
Table Of FORECAST: PSORIATIC ARTHRITIS (Published on 16 October 2017)
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Cimzia (Certolizumab Pegol)
Cosentyx (Secukinumab)
Enbrel (Etanercept)
Humira (Adalimumab)
Orencia (Abatacept)
Otezla (Apremilast)
Remicade (Infliximab)
Simponi (Golimumab)
Stelara (Ustekinumab)
Taltz (Ixekizumab)
Tremfya (Guselkumab)
Xeljanz (Tofacitinib)
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Cimzia (Certolizumab Pegol)
Cosentyx (Secukinumab)
Enbrel (Etanercept)
Humira (Adalimumab)
Orencia (Abatacept)
Otezla (Apremilast)
Remicade (Infliximab)
Simponi (Golimumab)
Stelara (Ustekinumab)
Taltz (Ixekizumab)
Tremfya (Guselkumab)
Xeljanz (Tofacitinib)
TREATMENT: PSORIATIC ARTHRITIS (Published on 16 October 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Compliance
Unmet Needs In Psoriatic Arthritis
Future Treatment Trends
Impact Of Biosimilars
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Compliance
Unmet Needs In Psoriatic Arthritis
Future Treatment Trends
Impact Of Biosimilars
EPIDEMIOLOGY: PSORIATIC ARTHRITIS (Published on 24 July 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: PSORIATIC ARTHRITIS (Published on 17 October 2017)
Overview
Executive Summary
Product Overview
Product Profile: Cimzia
Product Profile: Cosentyx
Product Profile: Enbrel
Product Profile: Humira
Product Profile: Orencia
Product Profile: Otezla
Product Profile: Remicade
Product Profile: Siliq
Product Profile: Simponi
Product Profile: Stelara
Product Profile: Taltz
Executive Summary
Product Overview
Product Profile: Cimzia
Product Profile: Cosentyx
Product Profile: Enbrel
Product Profile: Humira
Product Profile: Orencia
Product Profile: Otezla
Product Profile: Remicade
Product Profile: Siliq
Product Profile: Simponi
Product Profile: Stelara
Product Profile: Taltz
PSORIATIC ARTHRITIS PRICING, REIMBURSEMENT, AND ACCESS (Published on 24 June 2016)
Overview
Executive Summary
Market Context
Global Payer Insights
Us Pricing
Us Payer Insights
Us Reimbursement
Japan
Five Major Eu Markets Pricing
Five Major Eu Markets Payer Insights
Biosimilar Tnf-Alpha Inhibitors In The Five Major Eu Markets
France
Germany
Italy
Spain
Uk
Methodology
Executive Summary
Market Context
Global Payer Insights
Us Pricing
Us Payer Insights
Us Reimbursement
Japan
Five Major Eu Markets Pricing
Five Major Eu Markets Payer Insights
Biosimilar Tnf-Alpha Inhibitors In The Five Major Eu Markets
France
Germany
Italy
Spain
Uk
Methodology
PIPELINE: PSORIATIC ARTHRITIS (Published on 17 October 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Tremfya
Product Profile (Late Stage): Xeljanz
Product Profile (Late Stage): Upadacitinib
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Tremfya
Product Profile (Late Stage): Xeljanz
Product Profile (Late Stage): Upadacitinib
LIST OF FIGURES
Figure 1: Psoriatic arthritis sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: Psoriatic arthritis sales in the US, 2016–25
Figure 3: Psoriatic arthritis sales across the five major EU markets, by country, 2016–25
Figure 4: Sales of Humira, Enbrel, and their biosimilar versions across the US, Japan, and five major EU markets, 2016–25
Figure 5: Sales of Otezla versus Humira and Enbrel in the US, Japan, and five major EU markets, 2016–25
Figure 6: Sales of Otezla versus Xeljanz in the US, Japan, and five major EU markets, 2016–25
Figure 7: Sales of Cosentyx versus Stelara in the US, Japan, and five major EU markets, 2016–25
Figure 8: Sales of Cimzia, Simponi, and Taltz versus Cosentyx in the US, Japan, and five major EU markets, 2016–25
Figure 9: Sales of newly launched and pipeline agents in the US, Japan, and five major EU markets, 2016–25
Figure 10: The authors psoriatic arthritis forecast methodology
Figure 11: Price sources and calculations, by country
Figure 12: Cimzia sales for psoriatic arthritis across the US and five major EU markets, by country, 2016–25
Figure 13: Cosentyx sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Enbrel sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Humira sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Orencia sales for psoriatic arthritis across the US and five major EU markets, by country, 2016–25
Figure 17: Otezla sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 18: Remicade sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 19: Simponi sales for psoriatic arthritis across the US and five major EU markets, by country, 2016–25
Figure 20: Simponi Aria sales for psoriatic arthritis in the US, 2016–25
Figure 21: Stelara sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 22: Taltz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 23: Tremfya sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 24: Xeljanz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 25: Severity of diagnosed PsA patients, by country, 2016
Figure 26: PsA patients managed by each type of healthcare professional, by disease severity
Figure 27: Mean percentage of PsA patients receiving pharmacological therapy or non-pharmacological therapy, by disease severity
Figure 28: Top five regimens used for the treatment of mild PsA patients at first line, by country
Figure 29: Top five regimens used for the treatment of mild PsA patients at second line, by country
Figure 30: Top five regimens used for the treatment of moderate PsA patients at first line, by country
Figure 31: Top five regimens used for the treatment of moderate PsA patients at second line, by country
Figure 32: Usage of branded drugs in PsA patients across the US, Japan, and five major EU markets, by disease severity and country
Figure 33: Top five regimens used for the treatment of severe PsA patients at first line, by country
Figure 34: Top five brands used for the treatment of severe PsA patients at first line, by country
Figure 35: Remicade’s patient share in severe PsA patients in the US, Japan, and five major EU markets, by line of therapy
Figure 36: Top five brands used for the treatment of severe PsA patients at second line, by country
Figure 37: Compliance rates for PsA treatment, by formulation type and country
Figure 38: Expected shares of DMARD drug-treated PsA patients for currently approved and pipeline agents five years after launch, by disease severity
Figure 39: Physician confidence in prescribing biosimilars for PsA approved on the basis of indication extrapolation, by country
Figure 40: Summary of the future usage of biosimilars at one year and three years post-launch in the US, Japan, and five major EU markets
Figure 41: Trends in diagnosed prevalent cases of psoriatic arthritis in the US, Japan, and five major EU markets, by country, 2017–37
Figure 42: Cimzia for psoriatic arthritis – SWOT analysis
Figure 43: The authors drug assessment summary of Cimzia for psoriatic arthritis
Figure 44: The authors drug assessment summary of Cimzia for psoriatic arthritis
Figure 45: Cosentyx for psoriatic arthritis – SWOT analysis
Figure 46: The authors drug assessment summary of Cosentyx for psoriatic arthritis
Figure 47: The authors drug assessment summary of Cosentyx for psoriatic arthritis
Figure 48: Enbrel for psoriatic arthritis – SWOT analysis
Figure 49: The authors drug assessment summary of Enbrel for psoriatic arthritis
Figure 50: The authors drug assessment summary of Enbrel for psoriatic arthritis
Figure 51: Humira for psoriatic arthritis – SWOT analysis
Figure 52: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 53: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 54: Orencia for psoriatic arthritis – SWOT analysis
Figure 55: The authors drug assessment summary of Orencia for psoriatic arthritis
Figure 56: The authors drug assessment summary of Orencia for psoriatic arthritis
Figure 57: Otezla for psoriatic arthritis – SWOT analysis
Figure 58: The authors drug assessment summary of Otezla for psoriatic arthritis
Figure 59: The authors drug assessment summary of Otezla for psoriatic arthritis
Figure 60: Remicade for psoriatic arthritis – SWOT analysis
Figure 61: The authors drug assessment summary of Remicade for psoriatic arthritis
Figure 62: The authors drug assessment summary of Remicade for psoriatic arthritis
Figure 63: Siliq for psoriatic arthritis – SWOT analysis
Figure 64: The authors drug assessment summary of Siliq for psoriatic arthritis
Figure 65: The authors drug assessment summary of Siliq for psoriatic arthritis
Figure 66: Simponi for psoriatic arthritis – SWOT analysis
Figure 67: The authors drug assessment summary of Simponi for psoriatic arthritis
Figure 68: The authors drug assessment summary of Simponi for psoriatic arthritis
Figure 69: Stelara for psoriatic arthritis – SWOT analysis
Figure 70: The authors drug assessment summary of Stelara for psoriatic arthritis
Figure 71: The authors drug assessment summary of Stelara for psoriatic arthritis
Figure 72: Taltz for psoriatic arthritis – SWOT analysis
Figure 73: The authors drug assessment summary of Taltz for psoriatic arthritis
Figure 74: The authors drug assessment summary of Taltz for psoriatic arthritis
Figure 75: Tremfya for psoriatic arthritis – SWOT analysis
Figure 76: The authors drug assessment summary of Tremfya for psoriatic arthritis
Figure 77: The authors drug assessment summary of Tremfya for psoriatic arthritis
Figure 78: Xeljanz for psoriatic arthritis – SWOT analysis
Figure 79: The authors drug assessment summary of Xeljanz in psoriatic arthritis
Figure 80: The authors drug assessment summary of Xeljanz in psoriatic arthritis
Figure 2: Psoriatic arthritis sales in the US, 2016–25
Figure 3: Psoriatic arthritis sales across the five major EU markets, by country, 2016–25
Figure 4: Sales of Humira, Enbrel, and their biosimilar versions across the US, Japan, and five major EU markets, 2016–25
Figure 5: Sales of Otezla versus Humira and Enbrel in the US, Japan, and five major EU markets, 2016–25
Figure 6: Sales of Otezla versus Xeljanz in the US, Japan, and five major EU markets, 2016–25
Figure 7: Sales of Cosentyx versus Stelara in the US, Japan, and five major EU markets, 2016–25
Figure 8: Sales of Cimzia, Simponi, and Taltz versus Cosentyx in the US, Japan, and five major EU markets, 2016–25
Figure 9: Sales of newly launched and pipeline agents in the US, Japan, and five major EU markets, 2016–25
Figure 10: The authors psoriatic arthritis forecast methodology
Figure 11: Price sources and calculations, by country
Figure 12: Cimzia sales for psoriatic arthritis across the US and five major EU markets, by country, 2016–25
Figure 13: Cosentyx sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Enbrel sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Humira sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Orencia sales for psoriatic arthritis across the US and five major EU markets, by country, 2016–25
Figure 17: Otezla sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 18: Remicade sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 19: Simponi sales for psoriatic arthritis across the US and five major EU markets, by country, 2016–25
Figure 20: Simponi Aria sales for psoriatic arthritis in the US, 2016–25
Figure 21: Stelara sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 22: Taltz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 23: Tremfya sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 24: Xeljanz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 25: Severity of diagnosed PsA patients, by country, 2016
Figure 26: PsA patients managed by each type of healthcare professional, by disease severity
Figure 27: Mean percentage of PsA patients receiving pharmacological therapy or non-pharmacological therapy, by disease severity
Figure 28: Top five regimens used for the treatment of mild PsA patients at first line, by country
Figure 29: Top five regimens used for the treatment of mild PsA patients at second line, by country
Figure 30: Top five regimens used for the treatment of moderate PsA patients at first line, by country
Figure 31: Top five regimens used for the treatment of moderate PsA patients at second line, by country
Figure 32: Usage of branded drugs in PsA patients across the US, Japan, and five major EU markets, by disease severity and country
Figure 33: Top five regimens used for the treatment of severe PsA patients at first line, by country
Figure 34: Top five brands used for the treatment of severe PsA patients at first line, by country
Figure 35: Remicade’s patient share in severe PsA patients in the US, Japan, and five major EU markets, by line of therapy
Figure 36: Top five brands used for the treatment of severe PsA patients at second line, by country
Figure 37: Compliance rates for PsA treatment, by formulation type and country
Figure 38: Expected shares of DMARD drug-treated PsA patients for currently approved and pipeline agents five years after launch, by disease severity
Figure 39: Physician confidence in prescribing biosimilars for PsA approved on the basis of indication extrapolation, by country
Figure 40: Summary of the future usage of biosimilars at one year and three years post-launch in the US, Japan, and five major EU markets
Figure 41: Trends in diagnosed prevalent cases of psoriatic arthritis in the US, Japan, and five major EU markets, by country, 2017–37
Figure 42: Cimzia for psoriatic arthritis – SWOT analysis
Figure 43: The authors drug assessment summary of Cimzia for psoriatic arthritis
Figure 44: The authors drug assessment summary of Cimzia for psoriatic arthritis
Figure 45: Cosentyx for psoriatic arthritis – SWOT analysis
Figure 46: The authors drug assessment summary of Cosentyx for psoriatic arthritis
Figure 47: The authors drug assessment summary of Cosentyx for psoriatic arthritis
Figure 48: Enbrel for psoriatic arthritis – SWOT analysis
Figure 49: The authors drug assessment summary of Enbrel for psoriatic arthritis
Figure 50: The authors drug assessment summary of Enbrel for psoriatic arthritis
Figure 51: Humira for psoriatic arthritis – SWOT analysis
Figure 52: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 53: The authors drug assessment summary of Humira for psoriatic arthritis
Figure 54: Orencia for psoriatic arthritis – SWOT analysis
Figure 55: The authors drug assessment summary of Orencia for psoriatic arthritis
Figure 56: The authors drug assessment summary of Orencia for psoriatic arthritis
Figure 57: Otezla for psoriatic arthritis – SWOT analysis
Figure 58: The authors drug assessment summary of Otezla for psoriatic arthritis
Figure 59: The authors drug assessment summary of Otezla for psoriatic arthritis
Figure 60: Remicade for psoriatic arthritis – SWOT analysis
Figure 61: The authors drug assessment summary of Remicade for psoriatic arthritis
Figure 62: The authors drug assessment summary of Remicade for psoriatic arthritis
Figure 63: Siliq for psoriatic arthritis – SWOT analysis
Figure 64: The authors drug assessment summary of Siliq for psoriatic arthritis
Figure 65: The authors drug assessment summary of Siliq for psoriatic arthritis
Figure 66: Simponi for psoriatic arthritis – SWOT analysis
Figure 67: The authors drug assessment summary of Simponi for psoriatic arthritis
Figure 68: The authors drug assessment summary of Simponi for psoriatic arthritis
Figure 69: Stelara for psoriatic arthritis – SWOT analysis
Figure 70: The authors drug assessment summary of Stelara for psoriatic arthritis
Figure 71: The authors drug assessment summary of Stelara for psoriatic arthritis
Figure 72: Taltz for psoriatic arthritis – SWOT analysis
Figure 73: The authors drug assessment summary of Taltz for psoriatic arthritis
Figure 74: The authors drug assessment summary of Taltz for psoriatic arthritis
Figure 75: Tremfya for psoriatic arthritis – SWOT analysis
Figure 76: The authors drug assessment summary of Tremfya for psoriatic arthritis
Figure 77: The authors drug assessment summary of Tremfya for psoriatic arthritis
Figure 78: Xeljanz for psoriatic arthritis – SWOT analysis
Figure 79: The authors drug assessment summary of Xeljanz in psoriatic arthritis
Figure 80: The authors drug assessment summary of Xeljanz in psoriatic arthritis
LIST OF TABLES
Table 1: Psoriatic arthritis sales across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: Sales of Humira, Enbrel, and their biosimilar versions across the US, Japan, and five major EU markets ($m), 2016–25
Table 3: Sales of Otezla versus Humira and Enbrel in the US, Japan, and five major EU markets ($m), 2016–25
Table 4: Sales of Otezla versus Xeljanz in the US, Japan, and five major EU markets ($m), 2016–25
Table 5: Sales of Cosentyx versus Stelara in the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Sales of Cimzia, Simponi, and Taltz versus Cosentyx in the US, Japan, and five major EU markets ($m), 2016–25
Table 7: Summary of brands and molecules included in The authors psoriatic arthritis patient-based forecast
Table 8: Exchange rates used for calculating prices
Table 9: The authors pricing assumptions for Cimzia, by country
Table 10: Cimzia sales for psoriatic arthritis across the US and five major EU markets, by country ($m), 2016–25
Table 11: The authors pricing assumptions for Cosentyx, by country
Table 12: Cosentyx sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 13: The authors pricing assumptions for Enbrel, by country
Table 14: Enbrel sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 15: The authors pricing assumptions for Humira, by country
Table 16: Humira sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 17: The authors pricing assumptions for Orencia SC, by country
Table 18: The authors pricing assumptions for Orencia IV, by country
Table 19: Orencia sales for psoriatic arthritis across the US and five major EU markets, by country ($m), 2016–25
Table 20: The authors pricing assumptions for Otezla, by country
Table 21: Otezla sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 22: The authors pricing assumptions for Remicade, by country
Table 23: Remicade sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 24: The authors pricing assumptions for Simponi, by country
Table 25: The authors pricing assumptions for Simponi Aria in the US
Table 26: Simponi and Simponi Aria sales for psoriatic arthritis across the US and five major EU markets, by country ($m), 2016–25
Table 27: The authors pricing assumptions for Stelara, by country
Table 28: Stelara sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 29: The authors pricing assumptions for Taltz, by country
Table 30: Taltz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 31: The authors pricing assumptions for Tremfya, by country
Table 32: Tremfya sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Table 33: The authors pricing assumptions for Xeljanz, by country
Table 34: Xeljanz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 35: Specialists surveyed for the psoriatic arthritis primary research study, 2016
Table 36: Main patterns of disease in psoriatic arthritis, according to Moll and Wright
Table 37: Definition of mild, moderate, and severe PsA
Table 38: Key generic traditional disease-modifying antirheumatic drugs for the treatment of psoriatic arthritis
Table 39: Branded treatments available for psoriatic arthritis across the US, Japan, and five major EU markets
Table 40: PsA patients managed by each type of healthcare professional, by disease severity and country
Table 41: Patients receiving non-pharmacological therapy and pharmacological therapy, by disease severity and country (%)
Table 42: Distribution of PsA patients according to monotherapy/combination use across the US, Japan, and five major EU markets, by disease severity and country (%)
Table 43: Annual costs of Humira and Enbrel per patient, by country ($), 2016
Table 44: Relative importance of unmet needs in PsA treatment in the US, Japan, and five major EU markets, by country
Table 45: Future usage of biosimilar etanercept/infliximab, according to respondents aware of biosimilars, by country (%)
Table 46: Sources used for the epidemiological analysis of psoriatic arthritis in the US, Japan, and five major EU markets, by country
Table 47: Diagnosed prevalent cases of psoriatic arthritis in the US, Japan, and five major EU markets, by country, 2017–37
Table 48: Key marketed drugs for psoriatic arthritis
Table 49: Cimzia drug profile
Table 50: Cimzia pivotal trial data in psoriatic arthritis
Table 51: Cosentyx drug profile
Table 52: Cosentyx pivotal trial data in psoriatic arthritis
Table 53: Cosentyx ongoing late-phase trials in psoriatic arthritis
Table 54: Enbrel drug profile
Table 55: Enbrel pivotal trial data in psoriatic arthritis
Table 56: Enbrel late-phase trial data in psoriatic arthritis
Table 57: Humira drug profile
Table 58: Humira pivotal trial data in psoriatic arthritis
Table 59: Humira late-phase trial data in psoriatic arthritis
Table 60: Orencia drug profile
Table 61: Orencia pivotal trial data in psoriatic arthritis
Table 62: Otezla drug profile
Table 63: Otezla pivotal trial data in psoriatic arthritis
Table 64: Otezla’s late-phase trial data in psoriatic arthritis
Table 65: Remicade drug profile
Table 66: Remicade pivotal trial data in psoriatic arthritis
Table 67: Siliq drug profile
Table 68: Simponi drug profile
Table 69: Simponi pivotal trial data in psoriatic arthritis
Table 70: Simponi Aria pivotal trial data in psoriatic arthritis
Table 71: Stelara drug profile
Table 72: Stelara pivotal trial data in psoriatic arthritis
Table 73: Taltz drug profile
Table 74: Taltz Phase III data in psoriatic arthritis
Table 75: Taltz ongoing late-phase trials in psoriatic arthritis
Table 76: Marketed psoriatic arthritis products and approved indications in the US, Japan, and five major EU markets
Table 77: Late-stage candidates in development for psoriatic arthritis
Table 78: US pricing of key marketed drugs
Table 79: Top anti-inflammatory drug prescriptions filled by Medicare beneficiaries participating in Part B and D programs, 2014
Table 80: Specialty drug spend by Express Scripts members (inflammatory market)
Table 81: Formulary placement of psoriatic arthritis medications in selected commercial formularies
Table 82: Formulary placement of psoriatic arthritis medications in selected Medicare formularies
Table 83: Selected formulary practices of top 10 Medicare Part D and Medicare Advantage drugs: psoriasis and psoriatic arthritis
Table 84: Formulary placement of psoriatic arthritis drugs in selected Medicaid programs
Table 85: CVS Caremark and Express Scripts formulary exclusions for psoriatic arthritis drugs
Table 86: Prior authorization criteria for psoriatic arthritis drugs in major health insurers and pharmacy benefit managers
Table 87: Japan – pricing premiums given to medicines that can demonstrate benefit over comparators
Table 88: Price calculation methodologies for psoriatic arthritis drugs in Japan launched after 2008
Table 89: Pricing of key marketed psoriatic arthritis drugs in Japan
Table 90: Pricing of key psoriatic arthritis drugs in the five major EU markets, by country
Table 91: Access controls for psoriatic arthritis medications in the five major EU markets, by country
Table 92: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Table 93: Transparency Committee’s ASMR ratings and pricing implications
Table 94: Transparency Committee's SMR ratings and pricing implications
Table 95: Transparency Committee’s assessment of psoriatic arthritis treatments
Table 96: G-BA assessment of key psoriatic arthritis therapies
Table 97: Reimbursement conditions for psoriatic arthritis treatments in Italy
Table 98: Italian regional formulary decisions for psoriatic arthritis drugs
Table 99: Therapeutic positioning reports for psoriatic arthritis drugs in Spain
Table 100: Spanish Society of Hospital Pharmacy ratings
Table 101: NICE assessments of key psoriatic arthritis therapies
Table 102: Evidence summaries: new medicine for psoriatic arthritis drugs
Table 103: UK regional formulary decisions for psoriatic arthritis drugs
Table 104: SMC decisions on key psoriatic arthritis therapies
Table 105: Price sources and calculations for the US
Table 106: Price sources and calculations for the EU
Table 107: Exchange rates used for calculating branded drug prices
Table 108: Pipeline products in development for psoriatic arthritis
Table 109: Tremfya drug profile
Table 110: Tremfya Phase III trials in psoriatic arthritis
Table 111: Tremfya Phase IIa trial data in psoriatic arthritis
Table 112: Xeljanz drug profile
Table 113: Xeljanz Phase III data in psoriatic arthritis
Table 114: Xeljanz Phase III trials in psoriatic arthritis
Table 115: Upadacitinib drug profile
Table 116: Upadacitinib Phase III trials in psoriatic arthritis
Table 2: Sales of Humira, Enbrel, and their biosimilar versions across the US, Japan, and five major EU markets ($m), 2016–25
Table 3: Sales of Otezla versus Humira and Enbrel in the US, Japan, and five major EU markets ($m), 2016–25
Table 4: Sales of Otezla versus Xeljanz in the US, Japan, and five major EU markets ($m), 2016–25
Table 5: Sales of Cosentyx versus Stelara in the US, Japan, and five major EU markets ($m), 2016–25
Table 6: Sales of Cimzia, Simponi, and Taltz versus Cosentyx in the US, Japan, and five major EU markets ($m), 2016–25
Table 7: Summary of brands and molecules included in The authors psoriatic arthritis patient-based forecast
Table 8: Exchange rates used for calculating prices
Table 9: The authors pricing assumptions for Cimzia, by country
Table 10: Cimzia sales for psoriatic arthritis across the US and five major EU markets, by country ($m), 2016–25
Table 11: The authors pricing assumptions for Cosentyx, by country
Table 12: Cosentyx sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 13: The authors pricing assumptions for Enbrel, by country
Table 14: Enbrel sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 15: The authors pricing assumptions for Humira, by country
Table 16: Humira sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 17: The authors pricing assumptions for Orencia SC, by country
Table 18: The authors pricing assumptions for Orencia IV, by country
Table 19: Orencia sales for psoriatic arthritis across the US and five major EU markets, by country ($m), 2016–25
Table 20: The authors pricing assumptions for Otezla, by country
Table 21: Otezla sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 22: The authors pricing assumptions for Remicade, by country
Table 23: Remicade sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 24: The authors pricing assumptions for Simponi, by country
Table 25: The authors pricing assumptions for Simponi Aria in the US
Table 26: Simponi and Simponi Aria sales for psoriatic arthritis across the US and five major EU markets, by country ($m), 2016–25
Table 27: The authors pricing assumptions for Stelara, by country
Table 28: Stelara sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 29: The authors pricing assumptions for Taltz, by country
Table 30: Taltz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 31: The authors pricing assumptions for Tremfya, by country
Table 32: Tremfya sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country, 2016–25
Table 33: The authors pricing assumptions for Xeljanz, by country
Table 34: Xeljanz sales for psoriatic arthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 35: Specialists surveyed for the psoriatic arthritis primary research study, 2016
Table 36: Main patterns of disease in psoriatic arthritis, according to Moll and Wright
Table 37: Definition of mild, moderate, and severe PsA
Table 38: Key generic traditional disease-modifying antirheumatic drugs for the treatment of psoriatic arthritis
Table 39: Branded treatments available for psoriatic arthritis across the US, Japan, and five major EU markets
Table 40: PsA patients managed by each type of healthcare professional, by disease severity and country
Table 41: Patients receiving non-pharmacological therapy and pharmacological therapy, by disease severity and country (%)
Table 42: Distribution of PsA patients according to monotherapy/combination use across the US, Japan, and five major EU markets, by disease severity and country (%)
Table 43: Annual costs of Humira and Enbrel per patient, by country ($), 2016
Table 44: Relative importance of unmet needs in PsA treatment in the US, Japan, and five major EU markets, by country
Table 45: Future usage of biosimilar etanercept/infliximab, according to respondents aware of biosimilars, by country (%)
Table 46: Sources used for the epidemiological analysis of psoriatic arthritis in the US, Japan, and five major EU markets, by country
Table 47: Diagnosed prevalent cases of psoriatic arthritis in the US, Japan, and five major EU markets, by country, 2017–37
Table 48: Key marketed drugs for psoriatic arthritis
Table 49: Cimzia drug profile
Table 50: Cimzia pivotal trial data in psoriatic arthritis
Table 51: Cosentyx drug profile
Table 52: Cosentyx pivotal trial data in psoriatic arthritis
Table 53: Cosentyx ongoing late-phase trials in psoriatic arthritis
Table 54: Enbrel drug profile
Table 55: Enbrel pivotal trial data in psoriatic arthritis
Table 56: Enbrel late-phase trial data in psoriatic arthritis
Table 57: Humira drug profile
Table 58: Humira pivotal trial data in psoriatic arthritis
Table 59: Humira late-phase trial data in psoriatic arthritis
Table 60: Orencia drug profile
Table 61: Orencia pivotal trial data in psoriatic arthritis
Table 62: Otezla drug profile
Table 63: Otezla pivotal trial data in psoriatic arthritis
Table 64: Otezla’s late-phase trial data in psoriatic arthritis
Table 65: Remicade drug profile
Table 66: Remicade pivotal trial data in psoriatic arthritis
Table 67: Siliq drug profile
Table 68: Simponi drug profile
Table 69: Simponi pivotal trial data in psoriatic arthritis
Table 70: Simponi Aria pivotal trial data in psoriatic arthritis
Table 71: Stelara drug profile
Table 72: Stelara pivotal trial data in psoriatic arthritis
Table 73: Taltz drug profile
Table 74: Taltz Phase III data in psoriatic arthritis
Table 75: Taltz ongoing late-phase trials in psoriatic arthritis
Table 76: Marketed psoriatic arthritis products and approved indications in the US, Japan, and five major EU markets
Table 77: Late-stage candidates in development for psoriatic arthritis
Table 78: US pricing of key marketed drugs
Table 79: Top anti-inflammatory drug prescriptions filled by Medicare beneficiaries participating in Part B and D programs, 2014
Table 80: Specialty drug spend by Express Scripts members (inflammatory market)
Table 81: Formulary placement of psoriatic arthritis medications in selected commercial formularies
Table 82: Formulary placement of psoriatic arthritis medications in selected Medicare formularies
Table 83: Selected formulary practices of top 10 Medicare Part D and Medicare Advantage drugs: psoriasis and psoriatic arthritis
Table 84: Formulary placement of psoriatic arthritis drugs in selected Medicaid programs
Table 85: CVS Caremark and Express Scripts formulary exclusions for psoriatic arthritis drugs
Table 86: Prior authorization criteria for psoriatic arthritis drugs in major health insurers and pharmacy benefit managers
Table 87: Japan – pricing premiums given to medicines that can demonstrate benefit over comparators
Table 88: Price calculation methodologies for psoriatic arthritis drugs in Japan launched after 2008
Table 89: Pricing of key marketed psoriatic arthritis drugs in Japan
Table 90: Pricing of key psoriatic arthritis drugs in the five major EU markets, by country
Table 91: Access controls for psoriatic arthritis medications in the five major EU markets, by country
Table 92: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Table 93: Transparency Committee’s ASMR ratings and pricing implications
Table 94: Transparency Committee's SMR ratings and pricing implications
Table 95: Transparency Committee’s assessment of psoriatic arthritis treatments
Table 96: G-BA assessment of key psoriatic arthritis therapies
Table 97: Reimbursement conditions for psoriatic arthritis treatments in Italy
Table 98: Italian regional formulary decisions for psoriatic arthritis drugs
Table 99: Therapeutic positioning reports for psoriatic arthritis drugs in Spain
Table 100: Spanish Society of Hospital Pharmacy ratings
Table 101: NICE assessments of key psoriatic arthritis therapies
Table 102: Evidence summaries: new medicine for psoriatic arthritis drugs
Table 103: UK regional formulary decisions for psoriatic arthritis drugs
Table 104: SMC decisions on key psoriatic arthritis therapies
Table 105: Price sources and calculations for the US
Table 106: Price sources and calculations for the EU
Table 107: Exchange rates used for calculating branded drug prices
Table 108: Pipeline products in development for psoriatic arthritis
Table 109: Tremfya drug profile
Table 110: Tremfya Phase III trials in psoriatic arthritis
Table 111: Tremfya Phase IIa trial data in psoriatic arthritis
Table 112: Xeljanz drug profile
Table 113: Xeljanz Phase III data in psoriatic arthritis
Table 114: Xeljanz Phase III trials in psoriatic arthritis
Table 115: Upadacitinib drug profile
Table 116: Upadacitinib Phase III trials in psoriatic arthritis
